InvestorsHub Logo

stoneroad

11/12/18 6:03 PM

#158038 RE: rfj1862 #158035

In AF’s most recent article, he stated something along the lines of AMRN retail shareholders of making a “big mistake” by challenging him and Herper. WTF is up with that? Is he a reporter or a DB with an agenda? I think the answer is obvious!

smarterer

11/12/18 6:05 PM

#158039 RE: rfj1862 #158035

Herper's article in particular was borderline journalistic malpractice--just embarrassing.



Yeah, I don't think it was borderline, that was a ways in the rearview mirror. I just wanted to try and explain the process a bit. It's sausage-making, and good journalists--I know a couple--have a sense of where the line is, and work to try and present the full story of whatever they're covering, as opposed to advancing a perspective. These days there's a lot more of the latter everywhere, and Herper and Feuerstein are exhibit A for financial journalism.

Pretty sure Feuerstein has never taken a journalism class; not sure about Harper. There are ethical standards you're supposed to follow, but no enforcement mechanism I'm aware of.

VuBru

11/12/18 8:00 PM

#158071 RE: rfj1862 #158035

Exactly. For example:

Interview:
Herper Q: "What if I told you Reduce-It results show a notable increase in LDL in the placebo group, who got mineral oil?"

Responsible MD Answer: "Well, I might wonder whether using mineral oil could have exaggerated the effects of the study drug, but I would have to see more details to know whether this affected the primary results. Whether or not this is a problem would depend on how large those increases were and whether they were associated with actual MACE events"

Article:

Dr. so-and-so said "Mineral oil could have exaggerated the effects of the study drug," which may leave investors wondering whether all the purported beneficial effects of Vascepa may be questionable.